gynecological diseases
Conditions
Interventions
Bupivacaine group:Before anesthesia induction, ultrasound-guided stellate ganglion block was performed. The drug used was 0.25% bupivacaine injection 5 mL.
Bupivacaine liposome combined with bupivacaine group:Before anesthesia induction, ultrasound-guided stellate ganglion block was performed. The drugs used were 66 mg of Aixinping (liposomal bupivacaine
Control group:Before anesthesia induction, ultrasound-guided stellate ganglion block was performed, using 5 mL of normal saline as the drug.
Sponsors
Jilin University China-Japan Friendship Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 - 70 years old. Scheduled for elective gynecological laparoscopic surgery, and the type of surgery is in line with the following common procedures, including hysterectomy, uterine fibroid removal, ovarian cyst removal, and fallopian tube surgery. 2.The American Society of Anesthesiologists classification is I-II (good physical condition, without severe heart, lung, liver, or kidney dysfunction). There is no history of chronic pain before the surgery (defined as no continuous pain of = 3 months within 6 months before the surgery, such as chronic pelvic pain, cervical spondylosis, etc.), and no long-term use of analgesic drugs (such as non-steroidal anti-inflammatory drugs, opioid drugs), to avoid the influence of preoperative pain state or drug accumulation on postoperative pain assessment; 3.The preoperative VAS pain score is = 1 point.
Exclusion criteria
Exclusion criteria: 1.ASA classification = III grade, or coexisting severe cardiovascular or pulmonary diseases (such as congestive heart failure, acute exacerbation of chronic obstructive pulmonary disease, recent history of myocardial infarction (< 6 months)), liver and kidney failure (Child-Pugh grade B or above); 2.Coexisting neurological disorders (such as peripheral neuropathy, history of epilepsy, intracranial hypertension), which may affect the judgment of nerve block effect or increase the risk of drug neurotoxicity (such as the potential nerve injury risk of liposomal bupivacaine). 3.Pregnant or lactating women; mental disorders or cognitive dysfunction (such as Alzheimer's disease, schizophrenia), unable to cooperate with postoperative assessment or follow-up; 4.Refusal to participate in the study or expected inability to complete 72-hour follow-up (such as out-of-town patients, unstable contact information), resulting in the absence of key outcome indicators (such as 72-hour opioid consumption, long-term analgesic effect).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QoR-15 questionnaire score; | — |
Secondary
| Measure | Time frame |
|---|---|
| First exhaust time;the consumption of opioid drugs.;Postoperative satisfaction;VAS score ; | — |
Countries
China
Contacts
Public ContactHan Fanglei
Jilin University Chinese-Japanese Union Hospital
Outcome results
None listed